HIV/AIDS epidemic in Europe: HIV treatment and care

WHO/Europe helps countries, particularly low- and middle-income countries in the eastern part of the WHO European Region where 76% of new HIV infections are reported, to reach the goal of universal access to HIV prevention, treatment, care and support. Treatment and care for people living with HIV must be an integral part of a comprehensive and appropriate response to the HIV epidemic.

Treatment with antiretroviral drugs:

  • delays the progress of the disease
  • reduces disability
  • improves quality of life
  • increases life expectancy
  • prevents the transmission of HIV to others.

In 2013, WHO issued consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection and, in 2014, guidelines on HIV prevention, diagnosis, treatment and care for key populations. Together they offer a public health approach to scaling up treatment and containing HIV transmission.

Progress in providing HIV treatment and care

Countries in the Region have made significant progress in delivering HIV treatment and care to people living with HIV, including improved testing and counselling, laboratory monitoring and delivery of services.

ART use has been scaled up in the east, with 70 000 more patients receiving treatment in 2012 than in 2010. ART coverage increased from 23% (129 000) in 2010 to 35% (199 000) in 2012. This falls far short of the European coverage target of 80% by 2015. In the west, ART coverage is high, with 560 000 patients on ART in 2012, and most western European countries achieved or are on track to reach the 80% coverage target by 2015.

World Health Organization
Read The Full Story

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below